Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aziz Zaanan

Showing results (101-110 of 128) with videos related to

Pageof 13
Sort By:
European Journal of Cancer (Oxford, England : 1990)|August 28, 2025
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (PRODIGE 62-FFCD 1701-OESIRI)David Tougeron, Laurent Mineur, Aziz Zaanan, et al.
JAMA Oncology|October 7, 2017
Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical TrialsAziz Zaanan, Qian Shi, Julien Taieb, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 13, 2021
Metastatic colorectal carcinoma with signet-ring cells: Clinical, histological and molecular description from an Association des Gastro-Entérologues Oncologues (AGEO) French multicenter retrospective cohortMarion Allart, Florence Leroy, Stephano Kim, et al.
International Journal of Cancer|January 9, 2020
Small bowel adenocarcinoma: Results from a nationwide prospective ARCAD-NADEGE cohort study of 347 patientsThomas Aparicio, Julie Henriques, Sylvain Manfredi, et al.
NPJ Precision Oncology|June 26, 2026
Cell-free DNA dynamics and progression-free survival in metastatic gastroesophageal adenocarcinoma: insights from the REGIRI-PRODIGE 58 ancillary studyAlix Mérigout, Emmanuelle Samalin, Anthony Turpin, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 28, 2020
PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancerCamille Evrard, Christophe Louvet, Farid El Hajbi, et al.
Bulletin Du Cancer|February 15, 2020
[Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment]Romain Cohen, Thomas Pudlarz, Marie-Line Garcia-Larnicol, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 30, 2022
Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trialClélia Coutzac, Frederic Bibeau, Meher Ben Abdelghani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2026
Efficacy of Perioperative Pembrolizumab in Mismatch Repair Deficient/Microsatellite Unstable Localized Colorectal Cancers: Results of the Phase II Trial IMHOTEPChristelle de la Fouchardière, Aziz Zaanan, Aymeric de Montfort, et al.
Communications Medicine|April 24, 2025
Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinomaDavid Tougeron, Christophe Louvet, Jérôme Desramé, et al.
Pageof 13

Showing results (101-110 of 128) with videos related to

Sort By:
Pageof 13
European Journal of Cancer (Oxford, England : 1990)|August 28, 2025
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (PRODIGE 62-FFCD 1701-OESIRI)David Tougeron, Laurent Mineur, Aziz Zaanan, et al.
JAMA Oncology|October 7, 2017
Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical TrialsAziz Zaanan, Qian Shi, Julien Taieb, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 13, 2021
Metastatic colorectal carcinoma with signet-ring cells: Clinical, histological and molecular description from an Association des Gastro-Entérologues Oncologues (AGEO) French multicenter retrospective cohortMarion Allart, Florence Leroy, Stephano Kim, et al.
International Journal of Cancer|January 9, 2020
Small bowel adenocarcinoma: Results from a nationwide prospective ARCAD-NADEGE cohort study of 347 patientsThomas Aparicio, Julie Henriques, Sylvain Manfredi, et al.
NPJ Precision Oncology|June 26, 2026
Cell-free DNA dynamics and progression-free survival in metastatic gastroesophageal adenocarcinoma: insights from the REGIRI-PRODIGE 58 ancillary studyAlix Mérigout, Emmanuelle Samalin, Anthony Turpin, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 28, 2020
PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancerCamille Evrard, Christophe Louvet, Farid El Hajbi, et al.
Bulletin Du Cancer|February 15, 2020
[Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment]Romain Cohen, Thomas Pudlarz, Marie-Line Garcia-Larnicol, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 30, 2022
Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trialClélia Coutzac, Frederic Bibeau, Meher Ben Abdelghani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2026
Efficacy of Perioperative Pembrolizumab in Mismatch Repair Deficient/Microsatellite Unstable Localized Colorectal Cancers: Results of the Phase II Trial IMHOTEPChristelle de la Fouchardière, Aziz Zaanan, Aymeric de Montfort, et al.
Communications Medicine|April 24, 2025
Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinomaDavid Tougeron, Christophe Louvet, Jérôme Desramé, et al.
Pageof 13